Incannex Healthcare Inc. (IXHL)

Incannex’s lead IHL-42X program has moved into active Phase 2 execution for obstructive sleep apnea, with DReAMzz dosing underway across U.S. sites. The company also reports a debt-free balance sheet, roughly $68.4 million in unrestricted cashas of September 24, and intellectual-property protection extending to July 2040.